Tumor contamination of autologous peripheral blood stem/progenitor cell grafts occurs in a substantial proportion of high-risk breast cancer patients, and the possibility that such contamination may contribute to relapse has focused attention on methods for removal of the contaminating cells prior to transplantation. One such approach is positive selection of CD34 + cells. A fully automated immunomagnetic cell selection system has recently been introduced to facilitate the positive selection process. A multicenter randomized clinical trial was designed to evaluate the capacity of CD34 + cells isolated using the fully automated system to support prompt hematopoietic reconstitution following high-dose chemotherapy in high-risk breast cancer patients, as well as to assess the safety and tolerability of the CD34 + cell transplants. In recipients of isolated CD34 + cells, the median time to an absolute neutrophil count у500/l was 10 days, a value identical to that observed in patients receiving unfractionated apheresis collections. In the isolated CD34 + cell recipients median time to a platelet count у20 000/l was 12 days, compared with 10 days in the unfractionated cell group. There were no statistically significant differences between the groups in median time to neutrophil or platelet engraftment. Infusion of autologous cells was well tolerated by the study groups. There were no intergroup differences in the incidence of infections, need for platelet transfusions, or duration of hospitalization. Isolated CD34
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High-dose chemotherapy (HDC) with autologous hematopoietic stem/progenitor cell transplantation is increasingly performed in breast cancer patients with metastatic disease, as well as stage II/III patients with high numbers of involved axillary lymph nodes. 1, 2 The results of nine randomized clinical trials of HDC have thus far been reported: five adjuvant phase III trials [3] [4] [5] [6] [7] and four metastatic breast cancer trials. [8] [9] [10] [11] A meta-analysis of the four metastatic breast cancer trials revealed a statistically significant 11% absolute difference in event-free survival at 3 years favoring the HDC group. 12 An 8% absolute difference favoring the HDC group was observed in overall survival, although this was not statistically significant. The nine trials differed notably in design and follow-up period, and definitive inferences as to the efficacy of HDC cannot be drawn on the basis of the available data.
Relapse is the most common cause of death in patients with high-risk and metastatic breast cancer treated with HDC and hematopoietic stem/progenitor cell transplantation. 1 Relapse attributable to minimal residual disease could result from HDC-resistant cells harbored in the patient's body or from cells that contaminate stem/progenitor cell grafts. Tumor contamination of both autologous bone marrow and peripheral blood stem/progenitor cell grafts in breast cancer patients has been demonstrated. [13] [14] [15] [16] [17] In certain hematological malignancies and solid tumors, such as acute and chronic myeloid leukemia and neuroblastoma, reinfused cancer cells have been shown to contribute to relapse based upon gene marking. [18] [19] [20] While the contribution to relapse in breast cancer patients of contaminating tumor cells in transplant grafts remains to be shown, the possibility of such a contribution has stimulated a wide range of efforts to detect and remove contaminating cancer cells. 21 Among the widely investigated approaches to contaminating tumor cell removal is positive selection for CD34 + cells. The CD34 antigen is present primarily on stem and progenitor cells and is not detected on mature blood cells or non-Hodgkin's lymphoma, myeloma or most solid tumor cells. 22 The effectiveness of CD34 + cell enrichment in depleting breast tumor cells contaminating autologous transplant grafts has been demonstrated. [23] [24] [25] Positive selection of CD34 + cells can be accomplished by immunomagnetic techniques, which are typically based upon specific binding of target cells by anti-CD34 monoclonal antibody (MoAb). [26] [27] [28] The resulting CD34 + cellMoAb complexes are subsequently captured by secondary antibodies attached to the surface of paramagnetic microspheres. A final release step is then performed to free the CD34 + cells from the microspheres. In a recently reported randomized clinical trial of high-risk breast cancer patients undergoing HDC with autologous stem/progenitor cell support, CD34
+ cells isolated using a semi-automated immunomagnetic cell selection system promoted undelayed hematopoietic recovery compared with unfractionated peripheral blood apheresis collections, and no side-effects attributable to infusion of the isolated cells were observed. 29 With the increasingly widespread use of positive CD34 + cell selection in the preparation of transplant grafts has arisen a need for positive selection procedures that are more rapid, efficient, reproducible and standardized, as well as less labor intensive. A fully automated immunomagnetic cell selection system has recently been introduced that is designed to fulfill these requirements. With this system
CD34
+ cell selection procedures can be performed with minimal operator intervention within a total processing time of less than 3 h. 30 The system also employs a novel non-enzymatic peptide releasing agent that liberates target cells via specific competitive binding with minimal potential for alteration in cellular structure or function and without the presence of surface-bound anti-CD34 MoAb. 31, 32 The present study was designed to compare the ability of CD34 + cells isolated using the fully automated immunomagnetic cell selection system with that of unfractionated peripheral blood apheresis collections in promoting prompt hematopoietic recovery following HDC in high-risk and advanced breast cancer patients, as well as to compare the safety and tolerability of these two types of cell populations as transplant grafts. Overall and progression-free survivals post transplant were also compared but were not primary study endpoints.
Patients and methods

Patients
In this prospective randomized investigation, 114 breast cancer patients were enrolled at 10 study centers (Table 1) . Enrolled patients consisted of females between the ages of 27 and 63 years with metastatic disease or high-risk stage II/III adenocarcinoma of the breast who were eligible for institutional peripheral blood stem/progenitor cell transplant protocols. Patients with CNS disease, serious infections, including HIV, or poor performance status (ECOG Ͼ 1) were excluded. Patients who did not successfully mobilize (у20 CD34
+ cells/l in peripheral blood) were considered mobilization failures and were ineligible for randomization. Written informed consent was obtained from all participants, and the study was approved by each center's Institutional Review Board or Ethics Committee.
Initial evaluation
Initial evaluation of study patients included disease status, history and physical examination, diagnostic radiology as appropriate, and performance status. In addition, hematological assessment, including complete blood count (CBC) and platelet, reticulocyte, and differential white cell counts, evaluation of coagulation profile, blood chemistry assays, urinalysis, and microbiological screening were performed.
Mobilization
The design of the study is summarized in Figure 1 . Patients were mobilized using chemotherapy followed by recombinant human granulocyte colony-stimulating factor (rhG-CSF) or using rhG-CSF alone. Chemotherapy regimens employed for mobilization conformed to institutional protocols at the respective study centers (Table 1) . rhG-CSF (Neupogen; Amgen, Thousand Oaks, CA, USA) 5 g/kg/day or 300 g/day was administered subcutaneously starting 24-48 h after chemotherapy. In cases of mobilization using rhG-CSF alone the administered dose was 10 g/kg/day. Mobilization was monitored by determinations of circulating CD34
+ cells in peripheral blood and blood counts. Mobilization was judged successful when the peripheral blood CD34
+ cell concentration reached у20 CD34 + cells/l. Upon successful mobilization of hematopoietic stem/progenitor cells patients were randomized to receive either unfractionated autologous peripheral blood Bone Marrow Transplantation apheresis collections (unfractionated cell group) or isolated CD34
+ cells (CD34 + cell group) for hematologic rescue following myeloablative chemotherapy ( Figure 1 ).
Apheresis
In patients with circulating peripheral blood CD34
+ cells у20 CD34
+ cells/l and white blood count (WBC) у1000/l apheresis was performed using a CS-3000 Plus Blood Cell Separator (Fenwal Division, Baxter Healthcare Corporation, Round Lake, IL, USA) or a comparable blood cell collection system. A large-bore multi-lumen catheter served for venous access, and a total volume of approximately 10-12 l was processed in each daily session. Daily apheresis procedures continued until the target numbers of CD34 + cells had been collected. The target number for the unfractionated cell group was у2.5 × 10 6 CD34 + cells/kg, and у5 × 10 6 CD34 + cells/kg for the CD34 + cell group. The higher target number for the CD34 + cell group was needed to compensate for expected losses during the positive selection process.
In the CD34 + cell group an additional apheresis collection containing at least Ն1.5 × 10 6 CD34 + cells/kg was cryopreserved without further processing as a backup. Blood counts were monitored before and after each apheresis procedure. Apheresis collections that were not to be subjected to CD34
+ cell selection were cryopreserved in accordance with standard procedures of the respective study centers.
CD34
+ cell selection CD34 + cells were selected from peripheral blood apheresis collections using a fully automated immunomagnetic cell selection system (Isolex 300i Magnetic Cell Separator System, Nexell Therapeutics, Irvine, CA, USA). The components of this system include murine anti-CD34 + MoAb, a device for separating paramagnetic microspheres from mononuclear cell suspensions, a disposable set providing a sterile biocompatible fluid path, paramagnetic microspheres
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+ cell selection S Yanovich et al coated with sheep anti-murine antibodies (Dynabeads M450 paramagnetic beads; Dynal, Oslo, Norway), and nonenzymatic octapeptide releasing agent (PR34+, Nexell Therapeutics). The procedural steps performed by the fully automated system, which have been previously described, 33 are shown in Figure 2 . Briefly, cells were incubated with 2.5 mg of anti-CD34 MoAb in a total volume of 100 ml for 15 min at ambient temperature with occasional gentle mixing. Unbound antibody was removed by two washes with Ca 2+ -and Mg
2+
-free Dulbecco's phosphate-buffered saline containing 1% human serum albumin and 0.2% sodium citrate. MoAb-bound cells were rosetted with paramagnetic microspheres for 30 min at ambient temperature. Cell-bead complexes were then washed three times to remove nontarget cells. Thereupon, rosetted cells were dissociated from the antibody/bead complexes using octapeptide releasing agent. Finally, microspheres were removed by magnetic separation, and the CD34 + cells were collected.
Characterization of selected CD34
+ cells included determination of total nucleated cell (TNC) count, enumeration of CD34
+ cells by fluorescence-activated cell sorting analysis and evaluation of sterility and viability. CD34
+ cell enumeration was performed in accordance with methods established by each study center. In a previously reported multicenter randomized trial of a semi-automated immunomagnetic cell selection system, results of CD34 + cell enumeration obtained by the participating study centers were similar to those determined by a central reference laboratory. 29 Five of the centers participating in the present study were also participants in the previous randomized trial. After immunomagnetic selection CD34 + cells were cryo- preserved until the time of infusion according to respective study center standard procedures.
High-dose chemotherapy
HDC was conducted in accordance with protocols for which patients were eligible at the respective study centers (Table 1) . Adverse events occurring during HDC were documented.
Transplantation
Unfractionated cells or isolated CD34
+ cells were transplanted by intravenous infusion 24-72 h after HDC. Following infusion of unfractionated cells or isolated CD34 + cells, rhG-CSF was administered until absolute neutrophil count (ANC) у1000/l was observed for 3 consecutive days.
Concomitant treatment
During the course of the study, patients received concomitant treatment in the form of antiemetic, anti-infective and other medications and transfusions of blood products, as needed or as required by individual study center protocol. Generally, red blood cells were transfused to maintain hemoglobin у8-9 g/dl, and platelets to maintain platelet count Ͼ10 000-20 000/l or as required to prevent bleeding.
Follow-up
Post-transplant follow-up included daily CBC, differential white cells counts and platelet counts -until the counts
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+ cell selection S Yanovich et al 1169 were stable without transfusion support -and weekly blood chemistry assays. Neutrophil engraftment was defined as occurring on the first of 3 consecutive days upon which ANC was у500/l. Platelet engraftment was judged to have occurred on the first of 3 consecutive days upon which (1) no platelet transfusion support was rendered, and (2) platelet count was у20 000/l.
Adverse experiences during follow-up, including infections, were recorded. Patient evaluation at the time of hospital discharge included hematology, blood chemistry, disease assessment, and a brief physical examination with determination of performance status.
Post-discharge follow-up was scheduled monthly for 6 months after completion of HDC and included assessment of disease and performance status, documentation of adverse events and hematology studies. Further assessment of disease and performance status and hematology studies were conducted at 6 monthly intervals thereafter up to 2 years post transplant.
Data analysis SAS 6.11 statistical software (SAS Institute, Cary, NC, USA) and SPSS 8.0 statistical software (SPSS, Chicago, IL, USA) were used for data analysis and statistical testing of results obtained in the randomized study groups. As described below, some patients in the CD34 + cell group received unfractionated cells in addition to isolated CD34 + cells. Inclusion of these patients in the analysis of study results might mask inter-group differences in the primary study endpoints, namely, neutrophil and platelet engraftment. Accordingly, results are presented separately for patients receiving only CD34
+ cells (evaluable CD34 + cell group). In addition, results are presented on an intention-to-treat (ITT) basis for all patients randomized to receive isolated CD34 + cells regardless of unfractionated cell administration (ITT CD34 + cell group). The significance of inter-group disproportions in mobilization failure related to type of mobilization regimen was assessed by two-sided Fisher's exact test. Differences in baseline parameters and post-transplant transfusion requirements, antibiotic use and hospital stay were evaluated by t-test or Mann-Whitney U test. Rates of neutrophil and platelet engraftment and of overall and progression-free survival were calculated by the Kaplan-Meier method, and inter-group differences were assessed by log rank test. In addition, 95% confidence intervals (95% CI) for the difference in median time to engraftment were constructed by bootstrapping. Figure 3 summarizes the disposition of the study patients. Of the 114 patients enrolled, 92 were randomized, while 22 were judged ineligible for randomization, in 17 cantly higher proportion (P = 0.001) than that by rhG-CSF in conjunction with chemotherapy (5/73; 6.8%). Upon randomization 48 patients were assigned to the ITT CD34 + cell group and 44 to the unfractionated cell group.
Results
Patient disposition
Five of the 48 ITT CD34
+ cell group patients subsequently received unfractionated backup apheresis collection due to inability to collect the target CD34 + cell number. The remaining 43 patients were designated the evaluable CD34 + cell group. Results are reported below in parallel for both the ITT and evaluable CD34
+ cell groups as compared with the unfractionated cell group. One patient randomized to receive CD34
+ cells was not transplanted due to disease progression. Therefore, post-transplant results were unavailable for this patient.
Comparability of groups
Baseline patient and treatment data are listed in Table 2 . The study groups were similar with respect to age, body weight, disease stage, prior chemotherapy, mobilization regimen, apheresis collection composition and CD34 + cell dose transplanted. Also similar were baseline performance status, which was scored as ECOG р1 for all patients, and the distribution of metastatic sites. The median number of daily apheresis procedures performed in the unfractionated cell group (1.9; range, 1-4) was, however, significantly smaller (P = 0.01 and P = 0.008, respectively) than that of either the evaluable CD34 + cell group (2.8; range, 1-7) or the ITT CD34 + cell group (2.0; range, 1-7), presumably due to the higher target cell collection requirement for CD34 + cell recipients (у5 × 10 6 CD34 + cells/kg vs у2.5 × 10 6 CD34 + cells/kg for the unfractionated cell group).
Isolated CD34
+ cells
For the evaluable CD34 + cell group the median purity and yield of immunomagnetically isolated CD34
+ cells (n = 66 procedures) were 91.9% (range, 8.8-99.7%) and 54.5% (range, 3.4-601.4%), respectively. In 6/66 procedures (9.1%) involving this group purity was below 80%, and in 17/66 (25.8%) yield was less than 40%. Yield exceeded 100% in 4/66 such procedures (6.1%) and 130% in one (1.2%). It should be noted that in individual apheresis collections with comparatively low CD34
+ cell concentrations, In these two respective groups 3/41 patients (7.3%) and 6/45 patients (13.3%) received fewer than 2 × 10 6 CD34 + cells/kg. The mean infusion volumes in the evaluable CD34 + cell group (63 ml; range, 18-131 ml) and the ITT CD34 + cell group (70 ml; range, 18-200 ml) were 75.7% and 72.8% lower, respectively, than that in the unfractionated cell group (258 ml; range 50-712 ml). Mean exposure to dimethylsulfoxide, which was used as cryoprotectant at all but one of the study centers, was also therefore correspondingly lower in recipients of selected CD34 + cells. Adverse events (AEs) reported were similar for the study groups. There was no significant difference in the overall incidence of AEs related to cell infusion between study groups, and no serious AEs related to cell infusion were encountered. No infection was considered to be associated with infusion of isolated CD34 + cells. There were generally no significant inter-group differences in transfusion requirements, antibiotic administration or hospital stay (Table 3) . One exception was a statistically significant but small difference between the ITT CD34 + cell and unfractionated cell groups with respect to red blood cell units transfused. No significant differences were evident in time of infection onset or number of infections per patient.
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Engraftment
One patient in the evaluable CD34 + cell group died 7 days post transplant due to an accidental fall; engraftment was not documented for this patient. Platelet engraftment had not occurred by 200 days in one ITT CD34 + cell group patient. All other patients had documented neutrophil and platelet engraftment.
The median times to neutrophil engraftment for the evaluable CD34
+ cell group and the ITT CD34 + cell group were 10 days (range, 8-16 days) and 10 days (range, 8-22 days), respectively, as compared with 10 days (range, 8-20 days) for the unfractionated cell group. There was no statistically significant difference in the rate of neutrophil engraftment between the evaluable CD34 + cell group and the unfractionated cell group (P = 0.31) or between the ITT CD34 + cell group and the unfractionated cell group (P = 0.07), as shown in Figure 4a . The 95% CI for the inter-group difference in median time to neutrophil engraftment was −1 to 1 day for both the evaluable and ITT CD34
+ cell groups as compared with the unfractionated cell group.
Platelet engraftment rates for the study patients are shown in Figure 4b . The median times to platelet engraftment in the evaluable CD34 + cell group, the ITT CD34 + cell group and the unfractionated cell group were 12 days (range, 5-35 days), 12 days (range, 5-35 days) and 10 days (range, 6-37 days), respectively. The difference in Bone Marrow Transplantation rate of platelet engraftment between the evaluable CD34 + cell group and the unfractionated cell group was not statistically significant by log rank test (P = 0.06); whereas, the corresponding difference between the ITT CD34 + cell group and the unfractionated cell group was significant (P = 0.01). The 95% CI for the inter-group differences in median time to platelet engraftment were −1 to 3.5 days and −1 to 4 days for comparisons of the unfractionated cell group with the evaluable CD34
+ cell group and ITT CD34 + cell group, respectively. Since both confidence intervals contained zero, there was no evidence of a significant difference in median time to platelet engraftment either between the evaluable CD34 + cell group and the unfractionated cell group or between the ITT CD34 + cell group and the unfractionated cell group. On the basis of the observed 10 days median time to neutrophil and platelet engraftment in the unfractionated cell group, the present study afforded 86% statistical power to detect a significant 3 day prolongation in median time to neutrophil and platelet engraftment in either the evaluable CD34 + cell group or the ITT CD34
+ cell group as compared with the unfractionated cell group.
Survival
With more than 1 year of follow-up for most patients, no statistically significant difference was evident in the rates Significant difference in overall and progression-free survival was also absent upon stratification by disease stage. Thus, in neither stage II/III nor stage IV patients were these survival rates significantly different, either between the evaluable CD34
+ cell group and the unfractionated cell group or between the ITT CD34 + cell group and the unfractionated cell group. The statistical power of the present study was, however, limited in detecting significant inter-group survival differences.
Discussion
Since post-HDC neutropenia and thrombocytopenia can expose patients to the risk of life-threatening bacterial, viral and fungal infections, as well as render patients vulnerable to bleeding episodes, it is critical that autologous transplant grafts support rapid neutrophil and platelet engraftment. The present randomized study demonstrates that CD34 + cells isolated using a fully automated cell selection system promote undelayed hematopoietic reconstitution compared with unfractionated peripheral blood apheresis collections. Furthermore, no differences in post-transplant infection, platelet transfusion requirement or duration of hospital stay were evident between the two study groups. Both types of cell populations were well-tolerated, and adverse events attributable to cell infusions were infrequent and minor. The present findings are consistent with those of a recent randomized trial employing a semi-automated immunomagnetic cell selection system. 29 Mobilization failure was the most frequent ground for disqualifying patients from study participation, accounting for 17 of the 22 patients found ineligible for randomization. Additionally, results in five randomized patients were judged to be non-evaluable due to administration of unfrac- Figure 5 Kaplan-Meier analysis of (a) overall and (b) progression-free survival. Graphic conventions are the same as in Figure 4 . tionated backup cells necessitated by the inability to collect the target CD34 + cell number. In this heavily pretreated population inadequate CD34 + cell collections in some patients are not unexpected. Moreover, mobilization failure was associated in many cases with a mobilization regimen consisting of rhG-CSF alone rather than rhG-CSF in conjunction with chemotherapy.
The CD34 + cells selected using the fully automated system were of high purity, and target cell yield was sufficient for transplantation. While tumor cell contamination was not investigated as part of the present study, substantial log depletion of non-target B and T lymphocytes was demonstrated. Recently, use of a highly sensitive assay based upon immunomagnetic enrichment in conjunction with immunocytochemical analysis has provided evidence of a median 2.2 log depletion of breast tumor cells after positive CD34 + cell selection using the same fully automated immunomagnetic cell selection system as that of the present study. 34, 35 The highly sensitive assay also revealed tumor cell contamination in 71% of apheresis collections from patients with stage II, III or IV breast cancer for whom transplantation was indicated; whereas, only 23% of such collections appeared to be contaminated based upon conventional assay methods. Thus, the frequency of breast tumor contamination may be greater than previously appreciated, and a larger proportion of breast cancer patients may be at risk of relapse due to such contamination.
The positive selection process was rapid, and the need for operator intervention at multiple junctures during selection was reduced. The fully automated system thus reduced the labor intensity of selection as well as allowing greater standardization of procedures and potentially improving the reproducibility of results. The closed fluid path design of the fully automated system also reduces the risk of microbial contamination, which would be of particular concern during the post-HDC interval of neutropenia and increased susceptibility to infection.
One clear advantage of the selected CD34 + cells may be the markedly lower infusion volume needed for this type of transplant, posing less potential risk of side-effects resulting from cryoprotectant exposure and entailing less need for measures to avoid volume-related toxicities. The present study documented reduced infusion volume with selected cells; however, no difference in infusion-related toxicities was detected between recipients of isolated CD34 + cells vs
Fully automated CD34 + cell selection S Yanovich et al unfractionated cells. Nevertheless, the study was not specifically designed to detect such toxicities. In patients receiving cryopreserved autologous stem cells, dimethylsulfoxide has been found to be associated with adverse effects, including major cardiac complications, in a dosedependent manner. 36, 37 A survival benefit was not demonstrable in the present study. However, the study was not designed to detect such a benefit. The size and type of the patient population enrolled limited the power of the study to detect an inter-group difference in survival. The patient population enrolled in the present study included patients with metastatic disease, as well as high-risk stage II/III patients. Any potential benefit of tumor cell reduction may be difficult to demonstrate in patients with metastatic disease involving higher tumor burden; in the adjuvant setting the reduced tumor cell contamination afforded by selected CD34
+ cells may have greater potential to affect patient outcomes favorably. In addition, a greater positive impact of reduced graft contamination might be apparent in subsets of high-risk breast cancer patients who enjoy a more favorable prognosis due, for example, to having progesterone receptor-positive tumors. 38 The present study indicates that a fully automated immunomagnetic cell separation system provides an efficient and time-saving option for isolation of CD34
+ cells in peripheral blood apheresis collections from high-risk breast cancer patients. The isolated cells are high in purity and sufficient in number for use in autologous transplantations. The CD34
+ cells are comparable in effectiveness to unfractionated cells in supporting hematopoietic reconstitution. Larger scale, adequately powered randomized clinical investigations are needed to detect a survival advantage potentially resulting from depletion of contaminating tumor cells due to the positive selection process. The concomitant tumor cell depletion inherent in the positive selection process, in conjunction with improvements in chemotherapy protocols, may ultimately result in more favorable patient outcomes.
